microRNAs在前列腺癌精准放疗中的研究进展  

Research progress of microRNAs in precise radiotherapy for prostate cancer

作　　者：姜文华[1] 王海涛[1] Jiang Wenhua;Wang Haitao(Department of Radiotherapy,the Second Hospital of Tianjin Medical University,Tianjin 300211,China)

机构地区：[1]天津医科大学第二医院放疗科,300211

出　　处：《国际生物医学工程杂志》2018年第3期275-280,共6页International Journal of Biomedical Engineering

摘　　要：放射治疗（放疗）是前列腺癌（CaP）早期或进展期的一种非常重要的治疗手段，而放疗抵抗是当前放疗面临的最主要挑战。研究放疗抵抗的机制和开发新的克服放疗抵抗的治疗方法具有非常重要的意义。在CaP患者中，microRNAs（miRNAs）通常异常表达，而放疗可以显著改变miRNAs表达水平。越来越多的证据表明miRNAs和肿瘤放疗抵抗密切相关。miRNAs调节放疗抵抗的作用机制非常复杂，其可能的作用机制包括DNA损伤反应、细胞周期检查点激活、凋亡和自噬、肿瘤干细胞、乏氧等。有研究结果显示，miRNAs具有作为CaP放疗预后生物标志物和治疗靶点的潜力。以miRNAs为靶点的新技术联合放疗有望克服CaP放疗抵抗，有助于实现精准放疗，给患者带来希望。Radiotherapy is a very important treatment for early or advanced stage of prostate cancer （CAP）. Radioresistance is the most important challenge for current radiotherapy. It is of great importance to study the mechanisms of radioresistance and to develop new treatment strategies that can overcome radioresistance. In CaP patients, microRNAs （miRNAs） are usually abnormally expressed, and radiotherapy can significantly alter the expression levels of miRNAs. There are increasing evidences that miRNAs are closely related to tumor radioresistance. The mechanism of action of miRNAs in regulating radioresistanee is very complex. The possible mechanisms include DNA damage response, cell cycle checkpoint activation, apoptosis, autophagy, tumor stem cells, hypoxia, etc. The previous studies showed that miRNAs hold potential as prognostic biomarkers and therapeutic targets for CaP radiotherapy. New technologies targeting miRNAs combined with radiotherapy are expected to overcome CaP radioresistance, which will help to achieve precise radiotherapy, and bring hope to patients.

关 键 词：MICRORNAS 前列腺癌 放疗 放疗抵抗 

分 类 号：R737.25[医药卫生—肿瘤] R730.55[医药卫生—临床医学]